Latest news

CommercialJune 1, 2026

Pfizer and Innovent sign a $10 billion, 12-drug pact in a large wager on Chinese cancer medicine research

Followed by Bristol Myers Squibb, Pfizer is paying Innovent $650 million upfront for the privilege of collaborating on the...

ClinicalJune 1, 2026

Agios Halts Tebapivat Development in LR-MDS After Phase 2b Trial Misses Primary Endpoint

Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator tebapivat has failed a phase 2b study in lower-risk myelodysplastic syndromes (LR-MDS),...

InsightsMay 22, 2026

How Smaller Biotech Firms Are Competing With Big Pharma Using AI

Executive Summary Artificial intelligence is beginning to reshape competitive dynamics across the pharmaceutical and biotechnology industry. For decades, large pharmaceutical companies...

InsightsMay 22, 2026

The AI Talent War in Life Sciences Is Just Beginning

AI Talent:Executive Summary Artificial intelligence is no longer a tooling upgrade in life sciences—it is becoming a labor constraint problem...

ClinicalMay 22, 2026

BioMarin Reports Phase 3 Growth Improvements for Voxzogo in Hypochondroplasia

BioMarin has reported phase 3 results for its dwarfism...

InsightsMay 21, 2026

What Makes Life Sciences Data “AI-Ready”?

Executive Summary Artificial intelligence is rapidly becoming embedded across life...

InsightsMay 21, 2026

Synthetic Data in Healthcare: The Next Frontier or a Compliance Risk?

Executive Summary Synthetic data is rapidly emerging as one of the most closely watched developments in healthcare AI and life...

ClinicalMay 21, 2026

Immunovant Forced to Pay Out to Scrap FcRn Inhibitor Following Phase 3 Failure

Immunovant has announced that it has discontinued development of its first-generation FcRn inhibitor, batoclimab, roughly a month after the...

ClinicalMay 21, 2026

Parabilis Plans Phase 3 Trial of Zolucatetide for Desmoid Tumors

Parabilis Medicines is preparing to advance the development of zolucatetide, its Wnt/β-catenin pathway inhibitor, with plans to launch a...

CommercialMay 21, 2026

Incyte Expands Genesis AI Drug Discovery Partnership in Deal Worth Over $1 Billion

Incyte and Genesis Molecular AI have expanded their collaboration...

ClinicalMay 20, 2026

BioMarin’s BMN 401 Meets One Primary Goal but Misses Clinical Endpoint in Late-Stage ENPP1 Deficiency Trial

BioMarin Pharmaceutical said its experimental enzyme replacement therapy BMN...

RegulatoryMay 20, 2026

AstraZeneca receives approval for blood pressure medication

AstraZeneca's baxdrostat is approved by the FDA to treat blood pressure in patients with uncontrolled hypertension. The drug, to...

ClinicalMay 20, 2026

Regeneron’s Melanoma Drug Underperforms in Phase 3 Trial

A phase 3 study of Regeneron Pharmaceuticals’ LAG-3 inhibitor failed to achieve its primary endpoint, marking the company’s second...

InsightsMay 19, 2026

Will AI Replace Traditional CRO Models in Clinical Research?

Executive Summary Artificial intelligence is reshaping clinical research, but it is not simply replacing existing operational models—it is redistributing how...